NASDAQ · URGN
UroGen Pharma Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for URGN: Nov 04, 2026
UroGen Pharma Ltd. Ordinary Shares is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.38. The reported EPS for the same quarter last year was $-0.69.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.38 | $1.34 | $-0.07 | 4 |
| Dec 2026 | $0.07 | $0.51 | $-0.54 | 4 |
| Mar 2027 | $0.15 | $0.29 | $0.01 | 2 |
| Jun 2027 | $0.26 | $0.35 | $0.17 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · NASDAQ.com · The Motley Fool- Zacks · Oct 29, 9:00 AM EDTAgios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseAgios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 28, 9:52 AM EDTUroGen Reports No High-Grade Disease Progression In Five-Year JELMYTO Follow-Up; Stock Down(RTTNews) – UroGen Pharma Ltd. (URGN) announced final results from the five-year follow-up of its Phase 3 OLYMPUS study, demonstrating durable responses with JELMYTO (mitomycin) in adults with low-grade upper tract urothelial cancer (LG-UTUC).
- RTTNews · Oct 19, 12:06 PM EDTUroGen Secures FDA NDA Acceptance For Investigational Bladder Cancer Therapy(RTTNews) – UroGen Pharma Ltd. (URGN), a biotechnology company focused on urothelial and specialty cancers, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for UGN-103, an investigational treatment for adults with recurrent l
- NASDAQ.com · Oct 9, 4:24 PM EDTAfter Hours Most Active for Oct 9, 2026 : FTXR, NVDA, BKD, GRAB, TRVI, URGN, INDV, LUV, WFC, ESI, OSG, BACThe NASDAQ 100 After Hours Indicator is down -5.38 to 30,877.77. The total After hours volume is currently 134,392,844 shares traded.The following are the most active stocks for the after hours session: First Trust Nasdaq Transportation ETF (FTXR) is unchanged at $41.53, with 18
- Zacks · Sep 30, 9:11 AM EDTHere's Why You Should Add URGN Stock to Your Portfolio NowUroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
- Zacks · Aug 21, 9:55 AM EDTWall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a BetThe consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Aug 20, 11:32 AM EDTUroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics(RTTNews) – Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.
- RTTNews · Aug 20, 7:44 AM EDTIntraGel And UroGen Sign Strategic Collaboration To Advance Sustained-Release Oncology Therapies(RTTNews) – IntraGel Therapeutics, developer of next-generation long-acting injectables, has entered into a strategic collaboration and investment agreement with UroGen Pharma Ltd. (URGN) to advance investigational oncology therapies.
- RTTNews · Aug 17, 9:47 AM EDTUroGen Submits NDA For UGN-103 In Recurrent Non-Muscle Invasive Bladder Cancer(RTTNews) – UroGen Pharma Ltd. (URGN), a biotech company, on Monday announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for UGN-103 for intravesical solution, an investigational treatment for adults with recurrent low-grade intermediate-risk non-muscle in
- Zacks · Aug 14, 12:00 PM EDTAre You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great ChoiceDoes Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- The Motley Fool · Aug 12, 2:15 PM EDTUroGen (URGN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- BNK Invest · Aug 6, 7:25 AM EDTUroGen Pharma Reaches Analyst Target PriceIn recent trading, shares of UroGen Pharma Ltd (Symbol: URGN) have crossed above the average analyst 12-month target price of $44.75, changing hands for $46.43/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on va
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for UroGen Pharma Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.